Unraveling the Role of Innate Lymphoid Cells in AcuteMyeloid Leukemia.
AHR
AML
ILC
NK
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jan 2021
17 Jan 2021
Historique:
received:
12
12
2020
revised:
07
01
2021
accepted:
07
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
epublish
Résumé
Over the past 50 years, few therapeutic advances have been made in treating acute myeloid leukemia (AML), an aggressive form of blood cancer, despite vast improvements in our ability to classify the disease. Emerging evidence suggests the immune system is important in controlling AML progression and in determining prognosis. Natural killer (NK) cells are important cytotoxic effector cells of the innate lymphoid cell (ILC) family that have been shown to have potent anti-leukemic functions. Recent studies are now revealing impairment or dysregulation of other ILCs in various types of cancers, including AML, which limits the effectiveness of NK cells in controlling cancer progression. NK cell development and function are inhibited in AML patients, which results in worse clinical outcomes; however, the specific roles of other ILC populations in AML are just now beginning to be unraveled. In this review, we summarize what is known about the role of ILC populations in AML.
Identifiants
pubmed: 33477248
pii: cancers13020320
doi: 10.3390/cancers13020320
pmc: PMC7830843
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : K22 CA218466
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS106170
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223400
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA068458
Pays : United States
Organisme : NIH HHS
ID : CA068458
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA250244
Pays : United States
Organisme : NIH HHS
ID : 5K22CA218466-02
Pays : United States
Organisme : American Cancer Society
ID : RSG-20-051-01-LIB
Organisme : NCI NIH HHS
ID : R01 CA247550
Pays : United States
Organisme : NIH HHS
ID : CA208353
Pays : United States
Organisme : NIH HHS
ID : CA199447
Pays : United States
Organisme : NIH HHS
ID : CA210087
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129582
Pays : United States
Organisme : American Association for Cancer Research
ID : 17-20-46-MUND
Organisme : NCI NIH HHS
ID : R35 CA210087
Pays : United States
Références
Blood. 2014 Jul 31;124(5):700-9
pubmed: 24778151
Front Immunol. 2019 Sep 11;10:2180
pubmed: 31572388
Blood. 2011 Aug 4;118(5):1402-12
pubmed: 21540462
Ther Adv Vaccines Immunother. 2020 May 27;8:2515135520927164
pubmed: 32524070
Semin Immunol. 2019 Feb;41:101273
pubmed: 30979591
Stem Cells Dev. 2015 Dec 15;24(24):2886-98
pubmed: 26414401
Eur J Immunol. 2018 May;48(5):771-776
pubmed: 29336030
Nat Rev Immunol. 2020 Sep;20(9):552-565
pubmed: 32107466
J Exp Med. 2013 Feb 11;210(2):321-37
pubmed: 23359069
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Leuk Lymphoma. 2015 May;56(5):1398-405
pubmed: 25248875
Cancer Immunol Immunother. 2010 Jan;59(1):73-9
pubmed: 19526239
J Immunother. 2017 Jul/Aug;40(6):224-248
pubmed: 28557814
Clin Cancer Res. 2020 Feb 1;26(3):669-678
pubmed: 31672772
J Immunol. 2008 Aug 1;181(3):2227-37
pubmed: 18641363
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12391-6
pubmed: 23836658
Immunity. 2011 Aug 26;35(2):169-81
pubmed: 21820330
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Clin Cancer Res. 2017 Aug 1;23(15):4107-4118
pubmed: 28280089
Immunity. 2015 Oct 20;43(4):634-45
pubmed: 26488815
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
PLoS One. 2012;7(1):e30264
pubmed: 22279576
Nat Genet. 2011 Sep 04;43(10):1012-7
pubmed: 21892162
Am J Hematol. 2011 Feb;86(2):209-13
pubmed: 21264910
Cell. 2017 Mar 9;168(6):1086-1100.e10
pubmed: 28283063
Blood Adv. 2020 Apr 14;4(7):1350-1356
pubmed: 32267930
Blood. 2009 Dec 17;114(26):5331-41
pubmed: 19850741
Nat Med. 2005 Nov;11(11):1238-43
pubmed: 16227988
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Clin Transl Immunology. 2014 Jun 20;3(6):e17
pubmed: 25505965
Annu Rev Pharmacol Toxicol. 2003;43:309-34
pubmed: 12540743
Cell. 2017 Nov 2;171(4):795-808.e12
pubmed: 29056343
Haematologica. 2015 Jul;100(7):e257-60
pubmed: 25710455
Nat Genet. 2011 Sep 04;43(10):929-31
pubmed: 21892158
Haematologica. 2014 May;99(5):836-47
pubmed: 24488563
Am J Hematol. 2019 May;94(S1):S3-S9
pubmed: 30680780
Blood Adv. 2019 Jul 9;3(13):1970-1980
pubmed: 31266741
Blood. 2007 Jan 1;109(1):323-30
pubmed: 16940427
J Immunol. 2012 Aug 15;189(4):1567-76
pubmed: 22772450
PLoS One. 2014 Nov 21;9(11):e112945
pubmed: 25415278
Front Immunol. 2018 Jun 07;9:1252
pubmed: 29930552
Nat Rev Dis Primers. 2016 Mar 10;2:16010
pubmed: 27159408
Science. 2012 Jun 8;336(6086):1321-5
pubmed: 22674331
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Trends Immunol. 2013 Dec;34(12):573-82
pubmed: 24055329
Mol Pharmacol. 2010 Feb;77(2):247-54
pubmed: 19903824
Leukemia. 2012 Sep;26(9):2019-26
pubmed: 22446501
Blood. 2002 May 15;99(10):3661-7
pubmed: 11986221
Oncol Lett. 2018 Apr;15(4):5497-5504
pubmed: 29556297
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Oncoimmunology. 2017 Mar 24;6(12):e1307491
pubmed: 29209559
Immunity. 2012 Aug 24;37(2):339-50
pubmed: 22921121
Leukemia. 2020 Nov;34(11):3028-3041
pubmed: 32366935
Front Immunol. 2015 Nov 06;6:564
pubmed: 26594214
Nat Immunol. 2011 Nov 20;13(2):144-51
pubmed: 22101730
Anticancer Res. 2004 May-Jun;24(3b):1861-71
pubmed: 15274367
Blood. 2007 Jun 1;109(11):4816-24
pubmed: 17341666
J Exp Med. 2016 Oct 17;213(11):2249-2257
pubmed: 27670593
Blood. 2012 Mar 15;119(11):2665-74
pubmed: 22180440
Blood. 2014 Jul 31;124(5):812-21
pubmed: 24855210
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Leukemia. 2018 Feb;32(2):520-531
pubmed: 28725044
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Front Immunol. 2017 May 29;8:573
pubmed: 28611767
Blood. 2013 Aug 15;122(7):1316-24
pubmed: 23744585
Semin Immunol. 2014 Apr;26(2):132-7
pubmed: 24661538
Cell Rep. 2014 Jul 10;8(1):150-62
pubmed: 24953655
Blood. 2013 Apr 4;121(14):2669-77
pubmed: 23365458
Blood. 2018 Oct 25;132(17):1792-1804
pubmed: 30158248
Am J Cancer Res. 2018 Jun 01;8(6):1083-1089
pubmed: 30034945
Immune Netw. 2020 Feb 07;20(1):e6
pubmed: 32158594
Clin Cancer Res. 2018 Apr 15;24(8):1834-1844
pubmed: 29444931
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Blood Adv. 2019 Nov 26;3(22):3674-3687
pubmed: 31765481
Trends Pharmacol Sci. 2018 Mar;39(3):307-325
pubmed: 29254698
Immunity. 2005 Mar;22(3):295-304
pubmed: 15780987
Sci Transl Med. 2016 Sep 21;8(357):357ra123
pubmed: 27655849
Science. 2010 Sep 10;329(5997):1345-8
pubmed: 20688981
Leukemia. 2020 Nov;34(11):2914-2924
pubmed: 32546726
Trends Immunol. 2019 Oct;40(10):909-921
pubmed: 31500958
Cancer Sci. 2014 Aug;105(8):933-42
pubmed: 24890519
Semin Hematol. 2019 Apr;56(2):155-163
pubmed: 30926092
Br J Haematol. 2002 Jun;117(4):821-7
pubmed: 12060116
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Clin Exp Immunol. 1990 May;80(2):241-6
pubmed: 2357852
Blood. 2017 Oct 19;130(16):1857-1868
pubmed: 28835441
Leukemia. 2011 May;25(5):792-9
pubmed: 21274000
Blood. 2005 Jun 15;105(12):4878-84
pubmed: 15731175
Nat Immunol. 2017 Sep;18(9):1004-1015
pubmed: 28759001
Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6
pubmed: 32531207
Immunity. 2018 Nov 20;49(5):915-928.e5
pubmed: 30446384
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Oncotarget. 2017 Jul 25;8(30):49548-49563
pubmed: 28548938
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
Biol Blood Marrow Transplant. 2014 Apr;20(4):463-73
pubmed: 24434782
J Immunol. 2007 Apr 15;178(8):4947-55
pubmed: 17404276
J Immunol. 2017 Oct 15;199(8):2777-2793
pubmed: 28893953
Blood Adv. 2019 Dec 23;3(24):4312-4325
pubmed: 31869417
Eur J Immunol. 2012 Aug;42(8):1916-23
pubmed: 22865043
Cell Death Differ. 2014 Jan;21(1):100-12
pubmed: 24076586
J Immunol. 2020 Nov 15;205(10):2679-2693
pubmed: 33020148
Trends Immunol. 2018 Mar;39(3):222-239
pubmed: 29397297
Br J Cancer. 1988 Sep;58(3):368-72
pubmed: 3179190